Investor Relations header Spectrum Pharmaceuticals Investor Relations picture
     Â 
Oncology, Generics, Neurology Drugs About Spectrum Pharmaceuticals SPPI Investor Relations SPPI News
shadow area

Investor Relations

Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a focus in oncology. The Company's strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in its areas of focus; and, leveraging the expertise of partners around the world to assist it in the execution of its strategy.

Spectrum Pharmaceuticals’ stock is traded through the Nasdaq Global Market System

Ticker Symbol: SPPI

Recent Releases

Jan 27, 2012
Spectrum Pharmaceuticals Strengthens Commercial Operations

Jan 25, 2012
Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN®

View all releases »

Stock Information
NASDAQ:SPPI
$14.00   - 0.06
Jan 27, 2012
3:59 PM ET
Quotes delayed at least 20 minutes.
Information provided by eSignal.
Shareholder Tools

Search Investor Relations



 All contents © Copyright Spectrum Pharmaceuticals, Inc. 2012. All Rights Reserved.  Terms of Use